OVID - Alimera Sciences Reports Q1 Loss Misses Revenue Estimates | Benzinga
Alimera Sciences (NASDAQ: ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -200%. A quarter ago, it was expected that this eye drug developer would post earnings of $0.02 per share when it actually produced a loss of $0.07, delivering a surprise of -450%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Alimera Sciences, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $23.01 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 2.99%. This compares to year-ago revenues of $13.55 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the ...